Page last updated: 2024-09-03
tak 044 and candesartan
tak 044 has been researched along with candesartan in 1 studies
Compound Research Comparison
| Studies (tak 044) | Trials (tak 044) | Recent Studies (post-2010) (tak 044) | Studies (candesartan) | Trials (candesartan) | Recent Studies (post-2010) (candesartan) |
|---|---|---|---|---|---|
| 105 | 8 | 2 | 1,929 | 412 | 589 |
Protein Interaction Comparison
| Protein | Taxonomy | tak 044 (IC50) | candesartan (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.2769 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 5.9472 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.0652 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 9 | |
| Adenosine receptor A3 | Homo sapiens (human) | 1.2199 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 3 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.843 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.0652 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.0594 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0405 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ghiadoni, L; Magagna, A; Salvetti, A; Taddei, S; Virdis, A | 1 |
Trials
1 trial(s) available for tak 044 and candesartan
| Article | Year |
|---|---|
Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Hypertension; Male; Middle Aged; Nitric Oxide; Norepinephrine; omega-N-Methylarginine; Peptides, Cyclic; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Vasoconstrictor Agents; Vasodilator Agents | 2000 |